• About
• Links
• Contact
• Sitemap
• 

The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities

Summary

The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global blood disorders market. The report analyzes the markets for blood disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets

Scope

The scope of this report includes:

Annualized market data for the blood disorders market from 2001 to 2009, forecast forward to 2016

Analysis of the leading therapeutic segments including anemia, thrombosis, hemophilia, neutropenia and thrombocytopenia

Analysis of the blood disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan

Market characterization of the blood disorders market including market size, annual cost of therapy, sales volume and treatment usage patterns

Key drivers and barriers that have a significant impact on the market

Coverage of pipeline molecules in various phases of drug development

Competitive benchmarking of leading companies. The key companies studied in this report are Amgen, Inc., Sanofi-Aventis, Bristol-Myers Squibb, Centocor Ortho Biotech Inc., and Baxter.

Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global blood disorders market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

Align product portfolio to the markets with high growth potential

Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth

Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety

Develop key strategic initiatives by understanding key focus areas of leading companies

Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Table of Contents

1 Table of Contents 3

• 1.1 List of Tables 6
• 1.2 List of Figures 8

2 Global Blood Disorders Market: Introduction 11

• 2.1 Research Report Guidance 12

3 Global Blood Disorders Market: Market Overview 13

• 3.1 Introduction 13
• 3.2 Revenue Forecasts for the Global Blood Disorders Market 14
  • 3.2.1 Sales Value 14
  • 3.2.2 Sales Volume 15
  • 3.2.3 Annual Cost of Therapy 16
  • 3.2.4 Treatment Usage Patterns 17
  • 3.2.5 Generics’ Share in the Global Blood Disorders Market 22
• 3.3 Blood Disorders Market Drivers 24
  • 3.3.1 Steady Increase in the Prevalence Population, Particularly in Anemia, in the Top Five Countries in Europe 24
  • 3.3.2 Rapid Uptake of Biologics Products due to Better Efficacy and Safety in Diseases Such as Anemia, Hemophilia and Neutropenia 24
  • 3.3.3 Increase in the Prescription Population due to Patent Expiries of Expensive Biologic Drugs, Making Them More Affordable 24
  • 3.3.4 Increase in Conditions Such as Cancer and Cardiovascular Events will Increase the Prevalence of Blood Disorders 25
• 3.4 Blood Disorders Market Restraints 25
  • 3.4.1 Low Diagnosis Rate as the Contemporary Diagnostic Tools are Unable to Diagnose the Severe Forms of Blood Disorders 25
  • 3.4.2 Patent Expiries of Major Blockbusters Including Plavix, Lovenox, Aranesp, Neulasta, Procrit and Others Pose a Threat to Leading Players in the Market 25
  • 3.4.3 The Clearance of the Regulatory Pathway in the US Will Open up the World’s Largest Pharmaceutical Market to Biosimilar Players 26
  • 3.4.4 Sluggish Growth in the Annual Cost of Therapy for Blood Disorders is Expected To Drive Down the Growth Rate 26

4 Global Blood Disorders Market: Therapeutic Landscape 27

• 4.1 Anemia Market 27
  • 4.1.1 Introduction 27
  • 4.1.2 Sales Value 27
  • 4.1.3 Sales Volume 28
  • 4.1.4 Annual Cost of Therapy 30
  • 4.1.5 Treatment Usage Patterns 31
  • 4.1.6 Geographical Segmentation 36
  • 4.1.7 Generics’ Share of the Global Anemia Market 40
• 4.2 Thrombosis Market 42
  • 4.2.1 Introduction 42
  • 4.2.2 Sales Value 42
  • 4.2.3 Sales Volume 44
  • 4.2.4 Annual Cost of Therapy 45
  • 4.2.5 Treatment Usage Patterns 47
  • 4.2.6 Geographical Segmentation 52
  • 4.2.7 Generics’ Share of the Global Thrombosis Market 55
• 4.3 Hemophilia Market 56
  • 4.3.1 Introduction 56
  • 4.3.2 Sales Value 58
  • 4.3.3 Sales Volume 59
  • 4.3.4 Annual Cost of Therapy 60
  • 4.3.5 Treatment Usage Patterns 62
  • 4.3.6 Geographical Segmentation 67
  • 4.3.7 Generics’ Share in the Global Hemophilia Market 70
• 4.4 Neutropenia Market 72
  • 4.4.1 Introduction 72
  • 4.4.2 Sales Value 73
  • 4.4.3 Sales Volume 74
  • 4.4.4 Annual Cost of Therapy 75
  • 4.4.5 Treatment Usage Patterns 77
  • 4.4.6 Geographical Segmentation 82
  • 4.4.7 Generics’ Share in the Global Neutropenia Market 85

5 Global Blood Disorders Market: Geographical Landscape 88

• 5.1 Geographical Break-up 88
• 5.2 The US 91
  • 5.2.1 Sales Value 91
  • 5.2.2 Sales Volume 92
  • 5.2.3 Annual Cost of Therapy 93
  • 5.2.4 Treatment Usage Patterns 94
• 5.3 Top Five Countries in Europe 98
  • 5.3.1 Sales Value 98
  • 5.3.2 Sales Volume 100
  • 5.3.3 Annual Cost of Therapy 101
  • 5.3.4 Treatment Usage Patterns 103
• 5.4 Japan 107
  • 5.4.1 Sales Value 107
  • 5.4.2 Sales Volume 108
  • 5.4.3 Annual Cost of Therapy 110
  • 5.4.4 Treatment Usage Patterns 111

6 Global Blood Disorders Market: Pipeline Analysis 115

• 6.1 Introduction 115
  • 6.1.1 Research and Development Pipeline – Anemia 116
  • 6.1.2 Research and Development Pipeline – Thrombosis 117
  • 6.1.3 Research and Development Pipeline – Hemophilia 117
  • 6.1.4 Research and Development Pipeline – Neutropenia 118
• 6.2 Profiles of Key Late-Stage Drugs in the Blood Disorders Market 119
  • 6.2.1 Xarelto 119
  • 6.2.2 AVE-5026 120
  • 6.2.3 Apixaban 121
  • 6.2.4 Hematide 121
  • 6.2.5 MAXY–G34 122

7 Global Blood Disorders Market: Competitive Landscape 123

• 7.1 Market Share Analysis: Blood Disorders 123
• 7.2 Competitive Profiling 124
  • 7.2.1 Amgen 124
  • 7.2.2 Sanofi-Aventis 126
  • 7.2.3 Bristol-Myers Squibb 126
  • 7.2.4 Centocor Ortho Biotech Inc. 127
  • 7.2.5 Baxter 128

8 Global Blood Disorders Market: Strategic Consolidations 129

• 8.1 Overview 129
  • 8.1.1 GlaxoSmithKline Acquired JCR Pharmaceuticals Co Ltd. in December 2009 130
  • 8.1.2 Biovitrum AB Acquired Swedish Orphan International AB in November 2009 131
  • 8.1.3 LFB Biotechnologies Acquired GTC Biotherapeutics Inc in November 2009 131
  • 8.1.4 Watson Pharmaceuticals Acquired Arrow Group in June 2009 131
  • 8.1.5 Sanofi-Aventis SA Acquired Medley Pharmaceuticals in April 2009 131
  • 8.1.6 Merck & Co. Acquired Insmed Corporation in February 2009 132
  • 8.1.7 Pfizer Acquired Wyeth in January 2009 132
• 8.2 R&D Licensing Agreements 132
  • 8.2.1 Deals by Indication 132
  • 8.2.2 Deals by Phase 133
  • 8.2.3 Deals by Geography 133
  • 8.2.4 Deals by Licensing Type 134
  • 8.2.5 Deals by Value ($) 135
  • 8.2.6 Preclinical 135
  • 8.2.7 Phase II 136
  • 8.2.8 Phase III 138
  • 8.2.9 Filed/Approved 139

9 Global Blood Disorders Market: Appendix 140

• 9.1 Market Definitions 140
• 9.2 Abbreviations 140
• 9.3 Research Methodology 141
  • 9.3.1 Coverage 141
  • 9.3.2 Secondary Research 142
  • 9.3.3 Primary Research 142
  • 9.3.4 Forecasts 142
  • 9.3.5 Expert Panel Validation 144
• 9.4 Contact Us 145
• 9.5 Disclaimer 145
• 9.6 Sources 145

1.1 List of Tables

• Table 1: Blood Disorders Market, Global, Sales Value ($bn), 2001–2009 14
• Table 2: Blood Disorders Market, Global, Sales Value ($bn), 2009–2016 15
• Table 3: Blood Disorders Market, Global, Sales Volume, billion, 2001–2009 16
• Table 4: Blood Disorders Market, Global, Sales Volume, billion, 2009–2016 16
• Table 5: Blood Disorders Market, Global, Annual Cost of Therapy ($), 2001–2009 17
• Table 6: Blood Disorders Market, Global, Annual Cost of Therapy ($), 2009–2016 17
• Table 7: Blood Disorders Market, Global, Treatment Usage Patterns, 2001–2009 18
• Table 8: Blood Disorders Market, Global, Treatment Usage Patterns, 2009–2016 18
• Table 9: Blood Disorders Market, Global, Branded v/s Generic Drugs, $bn, 2001–2009 23
• Table 10: Blood Disorders Market, Global, Branded v/s Generic Drugs, $bn, 2009–2016 23
• Table 11: Blood Disorders Market, Global, Anemia Sales Value ($bn), 2001–2009 28
• Table 12: Blood Disorders Market, Global, Anemia Sales Value ($bn), 2009–2016 28
• Table 13: Blood Disorders Market, Global, Anemia Sales Volume (billion), 2001–2009 29
• Table 14: Blood Disorders Market, Global, Anemia Sales Volume (billion), 2009–2016 29
• Table 15: Blood Disorders Market, Global, Anemia Annual Cost of Therapy ($), 2001–2009 30
• Table 16: Blood Disorders Market, Global, Anemia Annual Cost of Therapy ($), 2009–2016 30
• Table 17: Blood Disorders Market, Global, Anemia Treatment Usage Patterns (million), 2001–2009 32
• Table 18: Blood Disorders Market, Global, Anemia Treatment Usage Patterns (million), 2009–2016 32
• Table 19: Blood Disorders Market, Global, Anemia Market Geographical Segmentation, 2001–2009 39
• Table 20: Blood Disorders Market, Global, Anemia Market Geographical Segmentation, 2009–2016 39
• Table 21: Blood Disorders Market, Global, Anemia Branded Vs Generics, 2001–2009 41
• Table 22: Blood Disorders Market, Global, Anemia Branded Vs Generics, 2009–2016 41
• Table 23: Blood Disorders Market, Global, Thrombosis Sales Value ($bn), 2001–2009 43
• Table 24: Blood Disorders Market, Global, Thrombosis Sales Value ($bn), 2009–2016 43
• Table 25: Blood Disorders Market, Global, Thrombosis Sales Volume (billion), 2001–2009 45
• Table 26: Blood Disorders Market, Global, Thrombosis Sales Volume (billion), 2009–2016 45
• Table 27: Blood Disorders Market, Global, Thrombosis Annual Cost of Therapy ($), 2001–2009 46
• Table 28: Blood Disorders Market, Global, Thrombosis Annual Cost of Therapy ($), 2009–2016 46
• Table 29: Blood Disorders Market, Global, Thrombosis Treatment Usage Patterns (million), 2001–2009 47
• Table 30: Blood Disorders Market, Global, Thrombosis Treatment Usage Patterns (million), 2009–2016 48
• Table 31: Blood Disorders Market, Global, Thrombosis Market Geographical Segmentation, 2001–2009 53
• Table 32: Blood Disorders Market, Global, Thrombosis Market Geographical Segmentation, 2009–2016 54
• Table 33: Blood Disorders Market, Global, Thrombosis Branded Vs Generics, 2001–2009 55
• Table 34: Blood Disorders Market, Global, Thrombosis Branded Vs Generics, 2009–2016 56
• Table 35: Blood Disorders Market, Global, Hemophilia Sales Value ($bn), 2001–2009 58
• Table 36: Blood Disorders Market, Global, Hemophilia Sales Value ($bn), 2009–2016 58
• Table 37: Blood Disorders Market, Global, Hemophilia Sales Volume (million), 2001–2009 59
• Table 38: Blood Disorders Market, Global, Hemophilia Sales Volume (million), 2009–2016 59
• Table 39: Blood Disorders Market, Global, Hemophilia Annual Cost of Therapy ($), 2001–2009 60
• Table 40: Blood Disorders Market, Global, Hemophilia Annual Cost of Therapy ($), 2009–2016 61
• Table 41: Blood Disorders Market, Global, Hemophilia Treatment Usage Patterns (000s), 2001–2009 62
• Table 42: Blood Disorders Market, Global, Hemophilia Treatment Usage Patterns (000s), 2009–2016 62
• Table 43: Blood Disorders Market, Global, Hemophilia Market Geographical Segmentation, 2001–2009 69
• Table 44: Blood Disorders Market, Global, Hemophilia Market Geographical Segmentation, 2009–2016 69
• Table 45: Blood Disorders Market, Global, Hemophilia Branded Vs Generics, 2001–2009 71
• Table 46: Blood Disorders Market, Global, Hemophilia Branded Vs Generics, 2009–2016 71
• Table 47: Blood Disorders Market, Global, Neutropenia Sales Value ($bn), 2001–2009 74
• Table 48: Blood Disorders Market, Global, Neutropenia Sales Value ($bn), 2009–2016 74
• Table 49: Blood Disorders Market, Global, Neutropenia Sales Volume (million), 2001–2009 75
• Table 50: Blood Disorders Market, Global, Neutropenia Sales Volume (million), 2009–2016 75
• Table 51: Blood Disorders Market, Global, Neutropenia Annual Cost of Therapy ($), 2001–2009 76
• Table 52: Blood Disorders Market, Global, Neutropenia Annual Cost of Therapy ($), 2001–2016 76
• Table 53: Blood Disorders Market, Global, Neutropenia Treatment Usage Patterns (million), 2001–2009 77
• Table 54: Blood Disorders Market, Global, Neutropenia Treatment Usage Patterns (million), 2009–2016 78
• Table 55: Blood Disorders Market, Global, Neutropenia Market Geographical Segmentation, 2001–2009 84
• Table 56: Blood Disorders Market, Global, Neutropenia Market Geographical Segmentation, 2009–2016 84
• Table 57: Blood Disorders Market, Global, Neutropenia Branded Vs Generics, 2001–2009 86
• Table 58: Blood Disorders Market, Global, Neutropenia Branded Vs Generics, 2009–2016 86
• Table 59: Blood Disorders Market, Global, Sales Value by Geography ($bn), 2001–2009 89
• Table 60: Blood Disorders Market, Global, Sales Value by Geography ($bn), 2009–2016 89
• Table 61: Blood Disorders Market, US, Sales Value ($bn), 2001–2009 91
• Table 62: Blood Disorders Market, US, Sales Value ($bn), 2009–2016 91
• Table 63: Blood Disorders Market, US, Sales Volume (billion), 2001–2009 92
• Table 64: Blood Disorders Market, US, Sales Volume (billion), 2009–2016 92
• Table 65: Blood Disorders Market, US, Annual Cost of Therapy ($), 2001–2009 93
• Table 66: Blood Disorders Market, US, Annual Cost of Therapy ($), 2009–2016 93
• Table 67: Blood Disorders Market, US, Treatment Usage Patterns (millions), 2001–2009 95
• Table 68: Blood Disorders Market, US, Treatment Usage Patterns (millions), 2009–2016 95
• Table 69: Blood Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2001–2009 99
• Table 70: Blood Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2009–2016 99
• Table 71: Blood Disorders Market, Top Five Countries in Europe, Sales Volume (billion), 2001–2009 101
• Table 72: Blood Disorders Market, Top Five Countries in Europe, Sales Volume (billion), 2009–2016 101
• Table 73: Blood Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2009 102
• Table 74: Blood Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2009–2016 102
• Table 75: Blood Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2001–2009 103
• Table 76: Blood Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2009–2016 104
• Table 77: Blood Disorders Market, Japan, Sales Value ($bn), 2001–2009 108
• Table 78: Blood Disorders Market, Japan, Sales Value ($bn), 2009–2016 108
• Table 79: Blood Disorders Market, Japan, Sales Volume (billion), 2001–2009 109
• Table 80: Blood Disorders Market, Japan, Sales Volume (billion), 2009–2016 109
• Table 81: Blood Disorders Market, Japan, Annual Cost of Therapy ($), 2001–2009 110
• Table 82: Blood Disorders Market, Japan, Annual Cost of Therapy ($), 2009–2016 110
• Table 83: Blood Disorders Market, Japan, Treatment Usage Pattern (million), 2001–2009 111
• Table 84: Blood Disorders Market, Japan, Treatment Usage Pattern (million), 2009–2016 112
• Table 85: Blood Disorders Market, Global, Major M&A Deals, 2009 130
• Table 86: Blood Disorders Market, Global, Licensing Agreements for Drugs in the Preclinical Stage (%), 2009–2010 135
• Table 87: Blood Disorders Market, Global, Licensing Agreements for Drugs in the Phase II Stage, 2009–2010 137
• Table 88: Blood Disorders Market, Global, Licensing Agreements for Drugs in the Phase III Stage, 2009–2010 138
• Table 89: Blood Disorders Market, Global, Licensing Agreements for Drugs in the Filed/Approved Stage, 2009–2010 139

1.2 List of Figures

• Figure 1: Blood Disorders Market, Global, Drivers and Restraints, 2009 13
• Figure 2: Blood Disorders Market, Global, Sales Value ($bn), 2001–2016 14
• Figure 3: Blood Disorders Market, Global, Sales Volume, billion, 2001–2016 15
• Figure 4: Blood Disorders Market, Global, Annual Cost of Therapy ($), 2001–2016 16
• Figure 5: Blood Disorders Market, Global, Therapeutic Usage Patterns, 2001–2016 17
• Figure 6: Blood Disorders Market, Global, Diseases Population (million), 2001–2016 19
• Figure 7: Blood Disorders Market, Global, Treatment Seeking Population (million), 2001–2016 20
• Figure 8: Blood Disorders Market, Global, Diagnosed Population (million), 2001–2016 21
• Figure 9: Blood Disorders Market, Global, Prescription Population (million), 2001–2016 22
• Figure 10: Blood Disorders Market, Global, Branded v/s Generic Drugs, $bn, 2001–2016 23
• Figure 11: Blood Disorders Market, Global, Market Indicators, 2009 24
• Figure 12: Blood Disorders Market, Global, Anemia Sales Value ($bn), 2001–2016 28
• Figure 13: Blood Disorders Market, Global, Anemia Sales Volume (billion), 2001–2016 29
• Figure 14: Blood Disorders Market, Global, Anemia Annual Cost of Therapy ($), 2001–2016 30
• Figure 15: Blood Disorders Market, Global, Anemia Treatment Usage Patterns (million), 2001–2016 31
• Figure 16: Blood Disorders Market, Global, Anemia Diseased Population (million), 2001–2016 33
• Figure 17: Blood Disorders Market, Global, Anemia Treatment Seeking Population (million), 2001–2016 34
• Figure 18: Blood Disorders Market, Global, Anemia Diagnosis Population (million), 2001–2016 35
• Figure 19: Blood Disorders Market, Global, Anemia Prescription Population (million), 2001–2016 36
• Figure 20: Blood Disorders Market, Global, Anemia Market Segmentation by Geography, 2009 and 2016 37
• Figure 21: Blood Disorders Market, Global, Anemia Market in the Top Five Countries in Europe, 2009 and 2016 37
• Figure 22: Blood Disorders Market, Global, Anemia Market Geographical Segmentation, 2001–2016 38
• Figure 23: Blood Disorders Market, Global, Anemia Market, Geography Benchmarking, 2009 40
• Figure 24: Blood Disorders Market, Global, Anemia Branded Vs Generics, 2001–2016 41
• Figure 25: Blood Disorders Market, Global, Anemia Market, Generics Share, 2009 and 2016 42
• Figure 26: Blood Disorders Market, Global, Thrombosis Sales Value ($bn), 2001–2016 43
• Figure 27: Blood Disorders Market, Global, Thrombosis Sales Volume (billion), 2001–2016 44
• Figure 28: Blood Disorders Market, Global, Thrombosis Annual Cost of Therapy ($), 2001–2016 46
• Figure 29: Blood Disorders Market, Global, Thrombosis Treatment Usage Patterns (million), 2001–2016 47
• Figure 30: Blood Disorders Market, Global, Thrombosis Diseased Population (million), 2001–2016 48
• Figure 31: Blood Disorders Market, Global, Thrombosis Treatment Seeking Population (million), 2001–2016 49
• Figure 32: Blood Disorders Market, Global, Thrombosis Diagnosis Population (million), 2001–2016 50
• Figure 33: Blood Disorders Market, Global, Thrombosis Prescription Population (million), 2001–2016 51
• Figure 34: Blood Disorders Market, Global, Thrombosis Market Segmentation by Geography, 2009 and 2016 52
• Figure 35: Blood Disorders Market, Global, Thrombosis Market in the Top Five Countries in Europe, 2009 and 2016 52
• Figure 36: Blood Disorders Market, Global, Thrombosis Market Geographical Segmentation, 2001–2016 53
• Figure 37: Blood Disorders Market, Global, Thrombosis Market, Geography Benchmarking, 2009 54
• Figure 38: Blood Disorders Market, Global, Thrombosis Branded Vs Generics, 2001–2016 55
• Figure 39: Blood Disorders Market, Global, Thrombosis Market, Generics Share, 2009 and 2016 56
• Figure 40: Hemophilia – Disease Cause, 2010 57
• Figure 41: Blood Disorders Market, Global, Hemophilia Sales Value ($bn), 2001–2016 58
• Figure 42: Blood Disorders Market, Global, Hemophilia Sales Volume (million), 2001–2016 59
• Figure 43: Blood Disorders Market, Global, Hemophilia Annual Cost of Therapy ($), 2001–2016 60
• Figure 44: Blood Disorders Market, Global, Hemophilia Treatment Usage Patterns (000s), 2001–2016 62
• Figure 45: Blood Disorders Market, Global, Hemophilia Diseased Population (000s), 2001–2016 63
• Figure 46: Blood Disorders Market, Global, Hemophilia Treatment Seeking Population (000s), 2001–2016 64
• Figure 47: Blood Disorders Market, Global, Hemophilia Diagnosis Population (000s), 2001–2016 65
• Figure 48: Blood Disorders Market, Global, Hemophilia Prescription Population (000s), 2001–2016 66
• Figure 49: Blood Disorders Market, Global, Hemophilia Market Segmentation by Geography, 2009 and 2016 67
• Figure 50: Blood Disorders Market, Global, Hemophilia Market in the Top Five Countries in Europe, 2009 and 2016 67
• Figure 51: Blood Disorders Market, Global, Hemophilia Market Geographical Segmentation, 2001–2016 68
• Figure 52: Blood Disorders Market, Global, Hemophilia Market, Geography Benchmarking, 2009 70
• Figure 53: Blood Disorders Market, Global, Hemophilia Branded Vs Generics, 2001–2016 71
• Figure 54: Blood Disorders Market, Global, Hemophilia Market, Generics Share, 2009 and 2016 72
• Figure 55: Blood Disorders Market, Global, Neutropenia Sales Value ($bn), 2001–2016 73
• Figure 56: Blood Disorders Market, Global, Neutropenia Sales Volume (million), 2001–2016 74
• Figure 57: Blood Disorders Market, Global, Neutropenia Annual Cost of Therapy ($), 2001–2016 76
• Figure 58: Blood Disorders Market, Global, Neutropenia Treatment Usage Patterns (million), 2001–2016 77
• Figure 59: Blood Disorders Market, Global, Neutropenia Diseased Population (million), 2001–2016 79
• Figure 60: Blood Disorders Market, Global, Neutropenia Treatment Seeking Population (million), 2001–2016 80
• Figure 61: Blood Disorders Market, Global, Neutropenia Diagnosed Population (million), 2001–2016 81
• Figure 62: Blood Disorders Market, Global, Neutropenia Prescription Population (million), 2001–2016 82
• Figure 63: Blood Disorders Market, Global, Neutropenia Market Segmentation by Geography, 2009 and 2016 82
• Figure 64: Blood Disorders Market, Global, Neutropenia Market in the Top Five Countries in Europe (%), 2009 and 2016 83
• Figure 65: Blood Disorders Market, Global, Neutropenia Market Geographical Segmentation, 2001–2016 84
• Figure 66: Blood Disorders Market, Global, Neutropenia Market, Geography Benchmarking, 2009 85
• Figure 67: Blood Disorders Market, Global, Neutropenia Branded Vs Generics, 2001–2016 86
• Figure 68: Blood Disorders Market, Global, Neutropenia Market, Generics Share, 2009 and 2016 87
• Figure 69: Blood Disorders Market, Global, Market Share by Geography, 2009 and 2016 88
• Figure 70: Blood Disorders Market, Global, Sales Value by Geography ($bn), 2001–2016 88
• Figure 71: Blood Disorders Market, Global, Geography Benchmarking, 2009 and 2016 90
• Figure 72: Blood Disorders Market, US, Sales Value ($bn), 2001–2016 91
• Figure 73: Blood Disorders Market, US, Sales Volume (billion), 2001–2016 92
• Figure 74: Blood Disorders Market, US, Annual Cost of Therapy ($), 2001–2016 93
• Figure 75: Blood Disorders Market, US, Treatment Usage Patterns (millions), 2001–2016 94
• Figure 76: Blood Disorders Market, US, Diseased Population (millions), 2001–2016 95
• Figure 77: Blood Disorders Market, US, Treatment Seeking Population (millions), 2001–2016 96
• Figure 78: Blood Disorders Market, US, Diagnosed Population (millions), 2001–2016 97
• Figure 79: Blood Disorders Market, US, Prescription Population (millions), 2001–2016 98
• Figure 80: Blood Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2001–2016 99
• Figure 81: Blood Disorders Market, Top Five Countries in Europe, Sales Volume (billion), 2001–2016 100
• Figure 82: Blood Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2016 102
• Figure 83: Blood Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2001–2016 103
• Figure 84: Blood Disorders Market, Top Five Countries in Europe, Diseased Population (million), 2001–2016 105
• Figure 85: Blood Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2001–2016 105
• Figure 86: Blood Disorders Market, Top Five Countries in Europe, Diagnosed Population (million), 2001–2016 106
• Figure 87: Blood Disorders Market, Top Five Countries in Europe, Prescription Population (million), 2001–2016 107
• Figure 88: Blood Disorders Market, Japan, Sales Value ($bn), 2001–2016 108
• Figure 89: Blood Disorders Market, Japan, Sales Volume (billion), 2001–2016 109
• Figure 90: Blood Disorders Market, Japan, Annual Cost of Therapy ($), 2001–2016 110
• Figure 91: Blood Disorders Market, Japan, Treatment Usage Pattern (million), 2001–2016 111
• Figure 92: Blood Disorders Market, Japan, Diseased Population (million), 2001–2016 112
• Figure 93: Blood Disorders Market, Japan, Treatment Seeking Population (million), 2001–2016 113
• Figure 94: Blood Disorders Market, Japan, Diagnosed Population (million), 2001–2016 114
• Figure 95: Blood Disorders Market, Japan, Prescription Population (million), 2001–2016 114
• Figure 96: Blood Disorders Market, Global, R&D Pipeline by Indication (%), March 2010 115
• Figure 97: Blood Disorders Market, Global, R&D Pipeline by Phase (%), March 2010 116
• Figure 98: Blood Disorders Market, Global, R&D Pipeline by Phase in Anemia Market (%), March 2010 116
• Figure 99: Blood Disorders Market, Global, R&D Pipeline by Phase in Thrombosis Market (%), March 2010 117
• Figure 100: Blood Disorders Market, Global, R&D Pipeline by Phase in Hemophilia Market (%), March 2010 118
• Figure 101: Blood Disorders Market, Global, R&D Pipeline by Phase in Neutropenia Market (%), March 2010 119
• Figure 102: Blood Disorders Market, Global, Market Share of Top Manufacturers (%), 2008 123
• Figure 103: Blood Disorders Market, Global, Revenue of Top Six Players ($m), 2006–2008 123
• Figure 104: Blood Disorders Market, Global, Competitive Analysis of Top Five Players, Market Share and CAGR (%), 2006–2008 124
• Figure 105: Blood Disorders Market, Global, M&A Deals by Indication (%), 2009 129
• Figure 106: Blood Disorders Market, Global, Major Licensing Agreements By Indication (%), 2009–2010 132
• Figure 107: Blood Disorders Market, Global, Major Licensing Agreements By Phase (%), 2009–2010 133
• Figure 108: Blood Disorders Market, Global, Major Licensing Agreements By Geography (%), 2009–2010 133
• Figure 109: Blood Disorders Market, Global, Major Licensing Agreements By Licensing Type (%), 2009–2010 134
• Figure 110: Blood Disorders Market, Global, Major Licensing Agreements By Deal Value (%), 2009–2010 135
• Figure 111: Research Methodology 141
• Figure 112: Research Market Forecasting Model 144

Other users found this report page using the following search terms: anemia thrombosis hemophilia neutropenia thrombocytopenia market hemophilia share thrombosis anemia future blooddisorders market drugs anemiaglobaldrugmarketprojections jr101 hemophiliamarketanalysis

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.